分子影像在抗癌药物研发中的应用
随着对癌症复杂生物学认识的提高,肿瘤药物研发不断增加,但进入临床试验的药物仅有限数量能获批成为标准治疗。分子影像通过放射性标记化合物并用SPECT或PET可视化,日益被视为在药物研发早期支持推进或终止决策的工具,本综述聚焦小分子、抗体和抗激素类抗癌药物研发中分子影像的当前应用。
要点
- 分子影像通过放射性标记化合物并用SPECT或PET可视化,可提供药物体内行为信息。
- 分子影像可全身显示药物靶点及靶点表达的异质性。
- 分子影像日益被视为在药物研发早期支持推进或终止决策的工具。
核心结论
- 分子影像日益被视为在药物研发早期支持推进或终止决策的工具。
研究设计与样本
- 本文为综述,聚焦分子影像在小分子、抗体和抗激素类抗癌药物研发中的当前应用。
主要发现
- 放射性标记可选用多种放射性核素,最好根据化合物大小和半衰期进行匹配。
- 分子影像可提供药物体内行为、全身药物靶点可视化及药物靶点表达异质性的信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of new oncology drugs has increased since the improved understanding of cancer's complex biology. The oncology field has become the top therapeutic research area for new drugs. However, only a limited number of drugs entering clinical trials will be approved for use as the standard of care for cancer patients. Molecular imaging is increasingly perceived as a tool to support go/no-go decisions early during drug development. It encompasses a wide range of techniques that include radiolabeling a compound of interest followed by visualization with SPECT or PET. Radiolabeling can be performed using a variety of radionuclides, which are preferably matched to the compound on the basis of size and half-life. Imaging can provide information on drug behavior in vivo, whole-body drug target visualization, and heterogeneity in drug target expression. This review focuses on current applications of molecular imaging in the development of small molecules, antibodies, and antihormonal anticancer drugs.
引用
- Waaijer SJH, Kok IC, Eisses B, et al. Molecular Imaging in Cancer Drug Development. J Nucl Med. 2018. PMID: 29371402. doi:10.2967/jnumed.116.188045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。